Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel-Carboplatin-Oregovomab vs Paclitaxel-Carboplatin-Placebo in Advanced Ovarian Cancer
2024-519218-30-00Phase 3Authorised
- Sponsor
- CanariaBio
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Paclitaxel + Carboplatin + Oregavomab with Paclitaxel + Carboplatin + Placebo (2 arms). Primary endpoint: Progression-Free Survival (PFS). Planned start Nov 2024; status: authorised.
02
Drugs
oregovomab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-519218-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519218-30-00.